HIV / AIDS

Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

The European Commission approved lenacapavir to treat multidrug-resistant HIV infection. The long-acting HIV treatment regimen will be marketed as Sunlenca and available in injection or tablet form.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

The study was longitudinal in nature, comparing at-risk people who became infected with HIV to at-risk people who did not.

Expanding Medicaid and reducing stigma can bolster equitable HIV PrEP access, Dr. Patrick Sullivan says.

After widespread implementation of HIV pre-exposure prophylaxis (PrEP) among gay and bisexual men in Australia, population-level incidence of chlamydia and gonorrhea stabilized, allaying fears that PrEP would lead to a rise in STIs, a recent study found.

At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.

After 5 years of treatment, fostemsavir improved immunologic response and virologic outcome in patients with highly resistant HIV infection.

HIV epidemics are emerging among key populations in the Middle East and North Africa, and the region ranks lowest globally in response indicators.

An HIV-positive woman in her 60s has recovered from a simultaneous heart and kidney transplant.

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.

Visceral leishmaniasis patients coinfected with HIV are vulnerable to other comorbidities including tuberculosis and cryptococcal meningitis but also to degrees of stigmatization and human rights issues.

A positive recommendation now heads to the European Commission, which can grant marketing authorization for 27 European Union member states.

The commitment to ending the HIV epidemic endures, despite drops in testing and new diagnoses during the COVID-19 pandemic.

In a phase 3 trial, if HIV patients received treatment for precancerous HSILs, their risk for developing anal cancer was reduced by half.

This small study had 2 phases, but patients saw HIV viral suppression for about 40 weeks after receiving the combination therapy infusions.

INSTIs have been thought to contribute to weight gain and metabolic syndrome, which in turn may contribute to cardiovascular events in HIV patients.

The South African National Department of Health has updated their HIV regimen recommendations for patients aged older than 10 years and more than 35 kg.

The start of Men’s Health Week offers an opportunity for men to get screened for a variety of health issues and be proactive with their health including those who might be at risk of HIV and may benefit from PrEP.

“It’s time to ensure widespread availability by promoting access to safe, effective, and sustainably priced medications, rather than providing incentives to prescribe higher-cost alternatives,” the authors said.

Adults living with HIV were more likely to have a breakthrough COVID-19 infection after vaccination, suggesting a need for additional vaccine doses in this population.

People infected with HIV are at a 4.5- to 12.9-fold increased risk of meningococcal disease compared to an otherwise healthy population, the study authors said.

The study authors determined that COVID-19 patients with HIV were 38% more likely to die than those without HIV.

Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.

The specialty of the prescribing clinician played a role in the appropriateness of the prescribing for managing ARI in patients with and without HIV.

In a poster presented at MAD-ID 2022, Margaret Pertzborn, PharmD, evaluated the efficacy of a PrEP Provider Toolkit on non-infectious disease provider comfort prescribing PrEP with their patients.

The FDA lifted a clinical hold on investigational lenacapavir for HIV treatment and pre-exposure prophylaxis. All clinical studies evaluating injectable lenacapavir can now resume.

Today, the International AIDS Vaccine Initiative (IAVI) and Moderna announced they will soon launch a phase 1 clinical trial for their HIV vaccine candidate, administered with mRNA technology to develop broadly neutralizing antibodies.